FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
FibroBiologics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$0.94−0.03 (-2.77%)
Close on Oct 19, 2026
- Market cap
- $5.92M
- P/E (TTM)
- –
- Dividend yield
- –
FibroBiologics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Market Cap | $6.29M | $166.30M |
| Enterprise Value | $2.77M | $88.19M |
| PB Ratio | 1.36 | 2.03 |
| P/TBV Ratio | 1.36 | 2.29 |
Income (trailing twelve months)
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Operating Income | -$16.73M | -$21.40M |
| Net Income | -$18.14M | -$22.46M |
| EBITDA | -$16.73M | -$16.91M |
| EPS (Diluted) | -$5.67 | -$0.83 |
Returns
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -660.1% | -53.2% |
| Return on Assets (ROA) | -166.1% | -40.9% |
| Return on Capital Employed (ROCE) | -292.7% | -38.1% |
Balance sheet
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.52M | $61.43M |
| Net Cash (Debt) | $3.52M | $15.35M |
| Net Cash Per Share | $0.53 | $0.66 |
| Equity (Book Value) | $4.64M | $49.09M |
| Book Value Per Share | $0.70 | $1.37 |
| Tangible Book Value | $4.64M | $23.52M |
| Working Capital | $3.64M | $76.81M |
Financial position
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Current Ratio | 2.64 | 3.34 |
| Quick Ratio | 1.59 | 2.44 |
| Interest Coverage | -77.81 | -6.26 |
Cash flow (trailing twelve months)
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.79M | -$12.35M |
| Capital Expenditures | -$6.00K | -$1.08M |
| Free Cash Flow | -$14.80M | -$20.22M |
| FCF Per Share | -$2.22 | -$0.42 |
Efficiency
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.21M | -$703.34K |
| Employee Count | 15 | 74 |
Dividends and yields
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Earnings Yield | -288.6% | -23.3% |
| FCF Yield | -235.4% | -8.72% |
Shares
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Shares Outstanding | 6,658,190 | 58,127,000 |
| Shares Change (YoY) | 112.8% | 10.9% |
| Shares Held by Institutions | 4.28% | 59.4% |
Taxes
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | FibroBiologics | Industry median |
|---|---|---|
| Altman Z-Score | -16.44 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from FibroBiologics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.